Novacyt S.A. (LSE:NCYT) has released its unaudited interim results for the first half of 2025, highlighting a period of consolidation aimed at supporting long-term growth. The company saw a modest rise in underlying group revenue, largely driven by strong demand for its reproductive health products in the APAC region. While statutory revenue decreased slightly, Novacyt successfully reduced its EBITDA loss through targeted cost-saving measures.
During the period, the company launched the LightBench® Discover instrument for genomic research laboratories, which has achieved promising early sales. Additionally, Novacyt received EU accreditation for its Yourgene QST*R Base assay, underlining its commitment to high-quality standards. With a solid balance sheet, the company is well-positioned to continue investing in R&D and expanding global adoption of its products.
About Novacyt S.A.
Novacyt S.A. is an international molecular diagnostics company offering a comprehensive portfolio of integrated technologies and services, with a focus on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing end-to-end solutions for human health, animal health, and environmental applications. Novacyt operates across three business segments—Clinical, Instrumentation, and Research Use Only—and maintains a presence in over 65 countries worldwide.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply